Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VERA 
Vera Therapeutics Inc (VERA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: VERA (3-star) is a STRONG-BUY. BUY since 27 days. Simulated Profits (22.42%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.75
1 Year Target Price $63.75
| 9 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 477.43% | Avg. Invested days 35 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.95B USD | Price to earnings Ratio - | 1Y Target Price 63.75 |
Price to earnings Ratio - | 1Y Target Price 63.75 | ||
Volume (30-day avg) 14 | Beta 1.23 | 52 Weeks Range 18.53 - 51.61 | Updated Date 10/14/2025 |
52 Weeks Range 18.53 - 51.61 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.24% | Return on Equity (TTM) -54.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1383737781 | Price to Sales(TTM) - |
Enterprise Value 1383737781 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.6 | Shares Outstanding 63823665 | Shares Floating 44832295 |
Shares Outstanding 63823665 | Shares Floating 44832295 | ||
Percent Insiders 0.97 | Percent Institutions 109.77 |
Upturn AI SWOT
Vera Therapeutics Inc
Company Overview
History and Background
Vera Therapeutics, Inc. (NASDAQ: VERA) is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients suffering from serious immunological diseases. Founded in 2016, Vera has progressed through preclinical and clinical stages with its lead product candidate, atacicept. It acquired Tricida in 2022, gaining access to atrasentan, another key asset in its pipeline.
Core Business Areas
- Immunological Diseases: Develops and commercializes therapies for immunological diseases like IgA nephropathy (IgAN).
- Kidney Diseases: Focuses on treatments for kidney diseases, including atrasentan for proteinuria reduction.
Leadership and Structure
The leadership team includes key executives overseeing research and development, clinical trials, and business operations. The organizational structure is typical of a biotech company with departments focused on drug development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Atacicept: Atacicept is a recombinant fusion protein targeting B lymphocyte stimulator (BLyS) and APRIL, being developed for IgA nephropathy (IgAN). Phase 3 trials are underway. Competitors include Calliditas Therapeutics (KDYNY) and Travere Therapeutics (TVTX).
- Atrasentan: Atrasentan is an oral endothelin A receptor antagonist (ERA) being developed for proteinuria reduction in glomerular diseases including IgAN. It was acquired from Tricida. Competitors include Travere Therapeutics (TVTX) and complex generics.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investments in research and development of new therapies. The immunological and kidney disease segments are growing due to increased prevalence of these conditions and advancements in treatment options.
Positioning
Vera Therapeutics is positioned as a late-stage clinical development company focused on bringing transformative therapies to patients with unmet needs in immunological and kidney diseases. Its competitive advantages include a promising pipeline and experienced leadership.
Total Addressable Market (TAM)
The IgA nephropathy market is expected to reach multi-billion dollars over the next 10 years. Vera Therapeutics' position in this TAM will depend on the successful completion and approval of its Phase 3 trials for Atacicept. The glomerular disease TAM is also expected to be significant in future years.
Upturn SWOT Analysis
Strengths
- Promising late-stage pipeline
- Experienced leadership team
- Targeting unmet needs in immunology and kidney diseases
- Strong cash position
Weaknesses
- Reliance on successful clinical trials
- Single product concentration risk (Atacicept)
- Commercialization risks
- Regulatory risks
Opportunities
- Successful clinical trial outcomes
- Expansion of pipeline through acquisitions or partnerships
- Regulatory approval and commercialization of atacicept
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Financing risks
Competitors and Market Share
Key Competitors
- KDYNY
- TVTX
- SNY
Competitive Landscape
Vera Therapeutics faces competition from established pharmaceutical companies and other biotechnology firms. Its competitive advantage lies in its targeted approach and promising clinical data. Disadvantages include limited resources compared to larger competitors.
Major Acquisitions
Tricida
- Year: 2022
- Acquisition Price (USD millions): 131
- Strategic Rationale: The acquisition of Tricida provided Vera Therapeutics with Atrasentan, expanding its pipeline and addressing a broader range of kidney diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily based on clinical development milestones and pipeline expansion.
Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary depending on the likelihood of these events.
Recent Initiatives: Recent initiatives include advancing the Phase 3 trial of atacicept, and exploring partnerships to expand the pipeline.
Summary
Vera Therapeutics is a clinical-stage biotech company with a promising lead candidate, atacicept, targeting IgAN. The company's acquisition of Tricida strengthened its pipeline, but its future success hinges on successful clinical trials and regulatory approvals. The company faces challenges from larger competitors and requires substantial financing to advance its programs. Overall, VERA presents a moderate risk and high reward profile given its potential to address unmet needs in kidney and immunological diseases, with a lot of uncertainty surrounding the successful completion of clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may vary. Investment in biotechnology companies carries significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vera Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-14 | Founder, President, CEO & Director Dr. Marshall W. Fordyce M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 192 | Website https://veratx.com |
Full time employees 192 | Website https://veratx.com | ||
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.